CeriBell, Inc.
NASDAQ:CBLLMedical - Devices
+$0.25 today
- Market cap
- $995.34M
- Beta
- 0.84
- P/E (TTM)
- -10.9
- EPS (TTM)
- -$1.60
Volume 0.41M
Average 0.29M
CBLL Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
CeriBell, Inc.NASDAQ: CBLL
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization dips below year-ago levels
Q1 FY2026 depreciation & amortization of $239K fell 28.7% year over year, behind the +3.0% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 17.9% from the prior quarter. Over 3 fiscal years it compounded at +39.2% a year.
Context
- Depreciation & amortization amounted to 1.5% of revenue in FY2025, down 0.2 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -28.7% toward the trailing-twelve-month pace of +3.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 1.34M USD
- Year-over-year change
- +17.5%
- 3-year CAGR
- +39.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.34M | +17.5% |
| FY2024 | 2024-12-31 | 1.14M | +34.7% |
| FY2023 | 2023-12-31 | 847K | +70.4% |
| FY2022 | 2022-12-31 | 497K | — |
Depreciation & Amortization vs competitors
How CBLL compares with its peers on the latest reported figures
- CBLL's LTM Mar 2026 depreciation & amortization of $1.25M is the 6th highest of the 7 companies compared; the peer median is $1.59M.
- Its year-over-year change of +3.0% is the 4th highest of 7, against a peer median of +1.3%.
- Depreciation & amortization amounts to 1.3% of revenue for CBLL, versus a peer median of 2.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $48.5M | -15.7% | -10.1% | 3.2% | |
| LTM Mar 2026 | $3.3M | +36.1% | +28.1% | 2.2% | |
| LTM Mar 2026 | $1.61M | -12.9% | +0.1% | 2.9% | |
| LTM Mar 2026 | $1.57M | -13.4% | -13.3% | 1.6% | |
| LTM Mar 2026 | $1.53M | +24.3% | +41.1% | 4.4% | |
CBLLCeriBell, Inc. | LTM Mar 2026 | $1.25M | +3.0% | +39.2% | 1.3% |
| LTM Mar 2026 | $777K | +15.6% | +22.4% | 1.3% | |
| Peer median (excluding CBLL) | $1.59M | +1.3% | +11.3% | 2.5% | |
Competitors are the stored peer set for CBLL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 25.92M | 45.23M | 65.44M | 89.06M |
| Cost of Revenue | 4.43M | 7.06M | 8.69M | 10.79M |
| Gross Profit | 21.49M | 38.16M | 56.75M | 78.27M |
| Gross Margin | 82.9% | 84.4% | 86.7% | 87.9% |
| Research & Development | 7.24M | 9M | 13.56M | 19.14M |
| Selling, General & Admin | 50.27M | 59.21M | 82.9M | 117.53M |
| Operating Expenses | 57.51M | 68.2M | 96.46M | 136.68M |
| Depreciation & Amortization | 497K | 847K | 1.14M | 1.34M |
| EBITDA | (35.06M) | (26.51M) | (37.32M) | (50.18M) |
| EBITDA Margin | -135.3% | -58.6% | -57.0% | -56.3% |
| Operating Income | (36.02M) | (30.04M) | (39.71M) | (58.4M) |
| Operating Margin | -139.0% | -66.4% | -60.7% | -65.6% |
| Interest Income | 0 | 0 | 0 | 0 |
| Interest Expense | 1.6M | 2.1M | 1.99M | 1.89M |
| Other Income / Expenses | (1.14M) | 588K | (746K) | 4.99M |
| Income Before Tax | (37.16M) | (29.45M) | (40.46M) | (53.41M) |
| Pre-Tax Margin | -143.4% | -65.1% | -61.8% | -60.0% |
| Income Tax Expense | 2K | 11K | 0 | 0 |
| Net Income | (37.16M) | (29.46M) | (40.46M) | (53.41M) |
| Net Margin | -143.4% | -65.1% | -61.8% | -60.0% |
| EPS (Basic) | (1.59) | (1.26) | (3.39) | (1.46) |
| EPS (Diluted) | (1.59) | (1.26) | (3.39) | (1.46) |
| Weighted Avg Shares | 23.32M | 23.32M | 11.95M | 36.54M |
| Weighted Avg Shares (Diluted) | 23.32M | 23.32M | 11.95M | 36.54M |
CeriBell, Inc.
NASDAQ:CBLL
Intrinsic Alpha fair value
Locked
Current Price
$25.63
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.